MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists

News   Apr 15, 2010

 
MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists
 
 
 

RELATED ARTICLES

Scientists Report The Development of a Potent New Medicine to Fight Addiction

News

Scientists report the development of a potent new medicine to fight addiction.

READ MORE

Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain Therapeutics

News

The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.

READ MORE

CRISPR Rescues Fragile X Syndrome Neurons

News

The gene editing technology CRISPR has been used to restore normal activity in neurons affected by Fragile X Syndrome.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE